|
The U.S. Food
and Drug Administration has approved use of the HeartMate assist
device, normally used to keep patients alive until a heart transplant,
as a permanent alternative to heart transplantation.
The battery-powered
heart pump, implanted just above the diaphragm, does not replace
a weekened heart but takes over much of the pumping performed
by the left ventricle.
A long waiting
list for heart transplants and the requirement that transplant
patients be in otherwise good health has resulted in a number
of patients receiving HeartMates to keep them going, and help
them improve their condition, while awaiting a heart transplant.
But the application
for permanent use of the device was filed after a study called
the Rematch trial found that patients using the HeartMate had
half the death rate of heart failure patients treated with medication
alone, as well as an improved quality of life.
With the FDA
decision, HeartMates now can be implanted in less-healthy patients
who are not candidates for a heart transplant.
"I think
it's really going to make a fundamental change in how we treat
heart failure," said Dr. Robert Kormos of the University
of Pittsburgh Medical Center.
LKormos estimated
that perhaps 25,000 patients a year might benefit from permanent
use of an implantable heart pump -- ten times the number who were
able to obtain heart transplants last year.
In addition
to the HeartMate, another device, the Novacor, is undergoing evaluation
as a permanent alternative to transplant.
The total
cost of implanting the pump is estimated to be about $160,000.
The federal Centers for Medicare and Medicaid Services covers
this cost for pumps used as a bridge to transplant but has not
yet established a reimbursement policy for their permanent use.
The HeartMate
is about 4 inches in diameter, 2 inches thick, and weighs just
over 2 pounds. Batteries for the device remain outside of the
patient's body, carried in holster-like garments.
Other
sources: FDA, Pittsburgh Post-Gazette
|